Early evolution of arterial oxygenation in severe community-acquired pneumonia: a prospective observational study.

Chien-Liang Wu,F. Lin,S. Lee,Chao-Hsien Lee,M. Peng,Pei-Jan Chen,H. Kuo

DOI: https://doi.org/10.1016/J.JCRC.2006.06.009

IF: 4.298

2007-06-01

Journal of Critical Care

Abstract:

What problem does this paper attempt to address?

Staged Management of Budd-Chiari Syndrome Caused by Co-Obstruction of the Inferior Vena Cava and Main Hepatic Veins.

Yu-Ling Sun,Yang Fu,Lin Zhou,Xiu-Xian Ma,Zhi-Wei Wang,Yan Wu

DOI: https://doi.org/10.1016/s1499-3872(13)60045-4

IF: 3.355

2013-01-01

Hepatobiliary & Pancreatic Diseases International

Abstract:BACKGROUND:Collateralized intra- and extra-hepatic routes in patients with Budd-Chiari syndrome (BCS) were important. This study aimed to investigate the feasibility and clinical outcomes of the staged management of BCS based on the degree of compensation provided by intra- or extra-hepatic collateral circulations.METHODS:A total of 103 adult patients with BCS caused by co-obstruction of the inferior vena cava (IVC) and main hepatic veins (MHVs) between March 2001 and October 2009 were enrolled in this study. Based on the pathological classification and degree of hemodynamic compensation by collateral circulations, treatment priority for IVC hypertension was determined in the first-stage treatment. Patients were deemed eligible for second-stage treatment when the first-stage treatment failed to relieve.RESULTS:Imaging results revealed that most patients had collateral circulations to different extents. Based on the degree of compensation provided by these collateral circulations, 74 patients underwent single-stage treatment for IVC hypertension, i.e., radiologic intervention (RI) for 61 patients and surgical procedures (SPs) for 13. One patient was treated for portal hypertension. Twenty-nine patients underwent second-stage treatment (25 underwent RI and SP, and 4 only SP). The general morbidity and mortality after all procedures were 8.3% and 1.5%, respectively. After a median follow-up of 35 months, 4 patients underwent second-stage treatment and 7 underwent recanalization of the IVC/MHVs. Two patients died of hepatocellular carcinoma and 1 died of graft obstruction.CONCLUSION:Staged management produces excellent outcomes for patients with BCS caused by co-obstruction of the IVC and MHVs.
Interventional and Surgical Treatment of Budd-Chiari Syndrome: A Report of 39 Cases

SHU Chang,LUO Ming-yao,JIANG Xiao-hua,LI Quan-ming,LI Ming

DOI: https://doi.org/10.16260/j.cnki.1009-2188.2011.01.010

2011-01-01

Abstract:Objective To explore the indications and effects for interventional and surgical treatment of Budd-Chiari syndrome.Methods A retrospective analysis of the clinical data of 39 B-CS patients treated by interventional and surgical therapy has been carried out.Among these patients,percutaneous transinferior vena cava angioplasty was performed in 3 cases,inferior vena cava PTA with stent deployed in 12 cases,radical resection in 9 cases,shunt or bypass procedure in 15 cases.Results The immediate successful rate for interventional and surgical treatment was 100%.The perioperative mortality was 0%.The inferior vena cava pressure was reduced by 5～24 cm H2O.A follow-up study showed that 13 cases returned to normal life,11 could be engaged in light manual work,8 could not do any manual work but take care of themselves.Among the radical resection group,one had recurrent pleural effusion until one year postoperatively,another had a relapse and was lost to follow-up thereafter.Conclusions Interventional therapy may be the first choice for most B-CS patients,but surgical treatment including radical resection and shunt also has their indications and unreplacement.Patients with different clinical types and different hemodynamic changes should be undergone different operations.
Analysis of Surgical Treatment Results in 120 Cases of Budd-Chiari Syndrome

Chen-yang Shen,Qing-fu Zeng,Qing-le Li,Yang Jiao,Xiao-ming Zhang

DOI: https://doi.org/10.3760/cma.j.issn.0529-5815.2012.04.007

2012-01-01

Abstract:OBJECTIVE:To evaluate the results of the surgical treatment of patients with Budd-Chiari syndrome (BCS).METHODS:The clinic data of 120 BCS patients who underwent various consecutive surgical treatments from July 2001 to October 2010 was analyzed. There were 82 male and 38 female patients, aging from 11 to 72 years with a mean age of (41 ± 13) years. All patients experienced various examinations to identify the pathological type of BCS. There were 5 cases of small hepatic veins type, 28 cases of large hepatic veins (LHV) type, 31 cases of inferior vena cava (IVC) type and 56 cases of combined obstruction of LHV and IVC. Totally, 25 patients experienced interventional treatment, include percutaneous transluminal angioplasty and/or stenting for stenosis of hepatic vein and/or IVC, 77 patients experienced open-thorax operation for BCS radical resection under protection of right atrium by-pass with extracorporeal circulation.RESULTS:Totally 97 cases were followed up from 1 to 120 months after various surgical treatment methods. Perioperative mortality was 6.2% (6/97). Follow-up period mortality was 8.2% (8/97). The restenosis of IVC and/or hepatic vein happened in 3 cases out of 25 cases in intervention treatment group in contrast with 15 cases out of 77 cases in radical resection group. The 5-year patency and survival rate of IVC/hepatic vein were 64.5% and 83.3%.CONCLUSIONS:The surgical treatment of BCS need to get accurate diagnosis and pathological classification firstly, then, to choose appropriate therapeutic strategies based on individual pathological classification. The BCS radical resection can be an alternative method in some particular pathological classifications and the cases who failed in interventional treatment.
Interventional Treatment of Budd-Chiari Syndrome:Report of 312 Cases

李晓强,段鹏飞,钱爱民,朱礼炜,郭劲松,余朝文,聂中林

DOI: https://doi.org/10.3760/j.issn:1007-631x.2004.10.006

2004-01-01

Abstract:Objective To evaluate interventional therapy for Budd-Chiari syndrome. Methods IVC venography was first carried out, the obliteration or stenosis in the IVC was opened or dilated with the hard tip of guid wire or puncture needle and balloon, then a stent was implanted. Results The procedure was successful in 271 out of 312 cases including IVC intervention in 260 cases, and hepatic vein intervention in 11 cases. IVC stent was used in 195 cases and hepatic vein stent in 1 case. There was no pulmonary embolism happened, acute renal failure occurred in 6 cases, hepatic coma in 1 case and acute heart failure in 21 cases. One patient died in this group and 2 were complicated with acute IVC thrombosis. Follow up of 6 to 104 mos was made in 203 cases with recurrence found in 21 cases. Conclusion Interventional therapy is indicated for most types of BCS with safe and effective results.
Advanced Imaging Techniques Used in Direct Portosystemic Shunt Creation in Budd-Chiari Syndrome with Complex Venous Anatomy

Sara Rostami,Jaclyn Fickert,Connor Morris,Michael Samuel,Doan Vu,Charles E. Ray,Ali Kord

DOI: https://doi.org/10.1055/s-0044-1779712

2024-03-15

Seminars in Interventional Radiology

Abstract:Budd-Chiari syndrome (BCS) is a relatively rare disease, most commonly found in middle-aged females, and is caused by hepatic vein blockage, except in Asian countries where it is more commonly found in males with inferior vena cava (IVC) obstruction.[1] The condition is classified as either primary or secondary depending on the source of the obstruction and whether it originates from within the venous system, such as in thrombosis, or external to the venous system, such as in compression by tumors of adjacent organs or polycystic kidney disease. Primary BCS is the most common manifestation and is most prevalent in those with underlying thrombogenic disorders such as primary myeloproliferative disease, essential thrombocythemia, and myelofibrosis.[2] Conditions that result in hypercoagulability such as pregnancy, oral contraceptive use, factor V mutation, antithrombin deficiency, protein C deficiency, and paroxysmal nocturnal hemoglobinuria can also cause primary BCS.[3] However, in most cases, the local cause of the thrombus formation cannot be identified. BCS generally becomes clinically evident after the occlusion of two or more major hepatic veins ([Figs. 1] and [2]). This causes a build-up of sinusoidal pressure and increased filtration of interstitial fluid into the liver capsule after the capacity of lymphatic drainage capacity has been exceeded. Resulting portal hypertension causes reduced hepatic blood flow and hepatocyte damage.[2] BCS and its progression can range in severity from asymptomatic, unobtrusive disease to acute, debilitating disease with significant morbidity.[4] [5] When symptomatic, BCS can present with abdominal pain and/or distention, ascites, hepatomegaly, jaundice, upper gastrointestinal bleeding, hepatic encephalopathy, and edema.[4] In chronic cases, patients can also present with renal impairment.[1] Article published online: 14 March 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

radiology, nuclear medicine & medical imaging
Endovascular treatment of Budd-Chiari syndrome with occlusion of hepatic veins

Wei-min ZHOU,Hao-rong WU,Xiao-qiang LI,Feng-en LIU,Shi-bin YANG,Ji-xin XIONG

DOI: https://doi.org/10.3760/cma.j.issn.1007-631X.2010.04.004

2010-01-01

Abstract:Objective To evaluate endovascular treatment of Budd-Chiari syndrome(BCS)with occlusion of hepatic veins.Methods Retrospective analysis on the clinical materials of 32 BCS cases with occlusion of hepatic veins was made.Four cases received inferior vena cava(IVC)angioplasty or stent implant and splenorenal shunt;Transfemoral vein or transjugular hepatic vein angioplasty was performed in 10 cases,and percutaneous transhepatic recanalization combined with transjugular and/or transfemoral vein angioplasty of hepatic veins was performed in 16 cases,respectively.Two cases failed therapy attempt.Results A failure to find the main hepatic vein in percutaneous transhepatic venography lead to the abandent of therapy in 2 cases.Hepatic vein angioplasty and IVC angioplasty was successful in the other 30 cases.The pressure of hepatic vein decreased from(43±8)cm H_2O to(16±4)cm H_2O(t=21.23,P<0.01).The symptoms were obviously relieved,ascites disappeared,abdominal distension palliated,chest and abdominal wall varicose veins collapsed one week after endovascular treatment.During perioperative procedure,2 cases with liver puncture bleeding were cured by laparotomy.The follow-up duration was 5 months to 65 months and mean(26.0±2.0)months.There was no stent migration and hepatic vein restenosis and occlusion.Chest and abdominal wall varicose veins disappeared and esophagus phlebeurysma were ameliorated as shown by esophageal barium series.There were no pulmonary embolism and death.Conclusions The procedure of endovascular treatment of BCS with occlusion of hepatic veins is simple,mini-traumatic and effective.
Modified Transjugular Intrahepatic Portosystemic Shunt In The Treatment Of Budd-Chiari Syndrome

X Wu,W Ding,J Cao,J Han,J Li

DOI: https://doi.org/10.1111/j.1742-1241.2008.01765.x

IF: 2.6

2010-01-01

International Journal of Clinical Practice

Abstract:Aims: The aim of this study was to determine the outcome of a modified transjugular intrahepatic portosystemic shunt (MTIPS) in the treatment of the Budd-Chiari syndrome (BCS, occlusion of the hepatic veins). Methods: Eleven patients with severe BCS were selected for MTIPS treatment. Three patients had an acute history (< 2 months) and eight had a subacute or a chronic course of the disease. All patients were associated with variceal bleeding and massive ascites. The diagnosis of BCS was established by duplex sonography, computed tomography scan, magnetic resonance imaging, angiography of hepatic veins and inferior vena cava, and liver biopsy. The shunt was established using conventional self-expandable stents with diameter of 10 cm in all patients. The mean follow-up was 60.55 +/- 42.76 months. Results: The shunt reduced the portosystemic pressure gradient from 30.32 +/- 7.69 to 9.08 +/- 3.43 mmHg and improved the portal flow velocity from 11.24 +/- 2.75 to 52.16 +/- 13.68 cm/s. Clinical symptoms as well as the biochemical test results improved significantly during 3 weeks after shunt treatment except for one death caused by hepatic failure. Ten patients are alive without clinical symptoms. Three revisions in two patients were needed during the follow-up. The inflation of stenosised shunt was performed in one patient, and the inflation of stenosised shunt and the reimplantation of stent in another patient. The other eight patients had no revisions. Conclusions: Modified transjugular intrahepatic portosystemic shunt provides an excellent outcome in patients with BCS (occlusion of the hepatic veins). It may be regarded as an option for the acute and long-term managements of these patients.
INTERVENTIONAL OR SEMI-INTERVENTIONAL TREATMENT FOR BUDD-CHIARI SYNDROME

Zhang Xiaoming,Wang Zhonggao

2003-01-01

Abstract:OBJECTIVE:Report the results of interventional or semi-interventional techniques for 173 patients with Budd-Chiari syndrome.METHOD:This group included 120 males and 53 females. The pathologic lesions composed of localized complete occlusion of inferior vena cava (IVC) (78), IVC stenosis (49), IVC membrane with a hole (37), membrane of hepatic vein (HV) (3), IVC thrombosis (4), IVC membrane with thrombosis (2) and IVC lesion with occlusion of HV (32). Treatment methods included that I: Percutaneous transinferior vena cava angioplasty (PTA) (76); II: IVC PTA with stent (59); III: Percutaneous transhepatic vein recanalization (3); IV: IVC thrombolysis through a catheter (4), V: Combined transcardiac and transfemoral venous membranotomy and balloon dilation (22); VI: V and stent (17); VII: Stenting during radical surgery (3); VIII: Additional operation after intervention (23).RESULTS:The immediate technique success rate for intervention was 90.1%, for the semi-intervention was 100%. The IVC pressure was reduced from 3 to 29 cmH2O. Complications occurred in 8 cases. The death rate was 2.9%. A follow-up study showed the recurrence rates were 14.5% in IVC PTA group, 1.7% in IVC PTA with stent, 18.2% in combined technique without stent and no recurrence was found in other groups.CONCLUSION:The PTA is the first choice for localized lesions. When elastic recoil occurs, immediate stenting is suggested. The semi-interventional approach is advised for PTA failure and more complicated cases. For those with both IVC lesion and occlusion of HV, the additional operation is needed after IVC intervention.
Clinical profile and outcomes of hepatocellular carcinoma in primary Budd-Chiari syndrome

Ankit Agarwal,Sagnik Biswas,Shekhar Swaroop,Arnav Aggarwal,Ayush Agarwal,Gautam Jain,Anshuman Elhence,Arun Vaidya,Amit Gupte,Ravi Mohanka,Ramesh Kumar,Ashwani Kumar Mishra,Shivanand Gamanagatti,Shashi Bala Paul,Subrat Kumar Acharya,Akash Shukla,Shalimar Shalimar

DOI: https://doi.org/10.4251/wjgo.v16.i3.699

2024-03-13

World Journal of Gastrointestinal Oncology

Abstract:BACKGROUND There is scant literature on hepatocellular carcinoma (HCC) in patients with Budd-Chiari syndrome (BCS). AIM To assess the magnitude, clinical characteristics, feasibility, and outcomes of treatment in BCS-HCC. METHODS A total of 904 BCS patients from New Delhi, India and 1140 from Mumbai, India were included. The prevalence and incidence of HCC were determined, and among patients with BCS-HCC, the viability and outcomes of interventional therapy were evaluated. RESULTS In the New Delhi cohort of 35 BCS-HCC patients, 18 had HCC at index presentation (prevalence 1.99%), and 17 developed HCC over a follow-up of 4601 person-years, [incidence 0.36 (0.22-0.57) per 100 person-years]. BCS-HCC patients were older when compared to patients with BCS alone (P = 0.001) and had a higher proportion of inferior vena cava block, cirrhosis, and long-segment vascular obstruction. The median alpha-fetoprotein level was higher in patients with BCS-HCC at first presentation than those who developed HCC at follow-up (13029 ng/mL vs 500 ng/mL, P = 0.01). Of the 35 BCS-HCC, 26 (74.3%) underwent radiological interventions for BCS, and 22 (62.8%) patients underwent treatment for HCC [transarterial chemoembolization in 18 (81.8%), oral tyrosine kinase inhibitor in 3 (13.6%), and transarterial radioembolization in 1 (4.5%)]. The median survival among patients who underwent interventions for HCC compared with those who did not was 3.5 years vs 3.1 mo (P = 0.0001). In contrast to the New Delhi cohort, the Mumbai cohort of BCS-HCC patients were predominantly males, presented with a more advanced HCC [Barcelona Clinic Liver Cancer C and D], and 2 patients underwent liver transplantation. CONCLUSION HCC is not uncommon in patients with BCS. Radiological interventions and liver transplantation are feasible in select primary BCS-HCC patients and may improve outcomes.

oncology,gastroenterology & hepatology
TIPS with a Twist - The Real Life Management of a Case of Budd-Chiari-related Acute Liver and Subsequent Multiple Organ Failure

Rares Craciun,Romeo Chira,Andrada Nemes,Horia Stefanescu,Simona Cocu,Bogdan Procopet

DOI: https://doi.org/10.2174/1573405620666230908111803

2023-09-08

Abstract:Introduction: Budd-Chari syndrome (BCS) is a rare condition defined by the obstruction of hepatic venous outflow. BCS is a relatively infrequent cause of acute liver failure (ALF), accounting for less than 1% of cases. Treatment for acute BCS consists of a stepwise approach, requiring anticoagulation, angioplasty, transjugular intrahepatic portosystemic shunt (TIPS), and liver transplantation. Case report: We present the case of a 31-year-old female patient with BCS, which led to ALF and subsequent multiple organ failure, which was successfully treated with TIPS and endovascular coil placement. Initial diagnostic workup revealed the complete obstruction of the hepatic venous outflow, spleno-mesenteric confluent thrombosis, and biochemical criteria of ALF. Her condition rapidly deteriorated towards multiple organ failure. At one point, the MELD score was 42, while the SOFA score predicted a mortality rate of >95%. Following continuous venovenous hemodiafiltration with cytokine adsorbent filters, TIPS was inserted, resulting in a portal pressure gradient (PPG) of 14 mmHg. Following TIPS, the patient had persistent ascites and later presented an episode of gastric variceal bleeding with endoscopic and surgical treatment failure. TIPS revision with further dilation led to a final PPG of 6 mmHg. During the procedure, selective embolization by coil placement of the spleno-gastric collateral circulation ultimately resolved the variceal bleeding. In the aftermath, the patient had complete organ failure remission and was successfully discharged with no ascites, encephalopathy, or significant impairment regarding daily life activities. Conclusion: In the rare setting of BCS complicated with ALF and portal hypertension-related complications, TIPS and endovascular embolization provide a unique, effective, and against-all-odd solution.
Radical Surgery under Genuine Direct Vision for the Treatment of Budd-Chiari Syndrome.

Xiao-Ming Zhang,Qing-Le Li

2006-01-01

Abstract:BACKGROUND:Budd-Chiari syndrome (BCS) develops with complete or incomplete obstruction of the hepatic veins (HV), the super hepatic inferior vena cava (IVC), or both. Various methods have been reported regarding the treatment of BCS. In this article, we present our preliminary experience with radical surgery in the treatment of Budd-Chiari syndrome under genuine direct vision.METHODS:In 13 patients aged from 17 to 48 years, the disease lasted from 3 months to 5 years. Membranous obstruction of the inferior vena cava (IVC) was observed in 3 patients, right hepatic venous (HV) membrane in 1, IVC membrane with distal thrombosis in 6, long-segment thrombosis of the IVC in 2, and IVC thrombosis caused by retroperitoneal tumor extending to the right atrium in 1.RESULTS:All lesions were successfully resected. Extracorporeal circulation was used in one patient, and the cell saver in 2 patients. No blood transfusion was given except for 3 patients receiving blood transfusion of 2000, 400, and 400 ml, respectively. One patient died of renal failure during the postoperative period. Signs and symptoms disappeared after the operation in the remaining patients.CONCLUSION:This new radical surgery gives access to the lesions under clear direct vision in further facilitating the correction needed.
Modified transjugular intrahepatic portosystemic shunt in the treatment of Budd‐Chiari syndrome

Xingjiang Wu,Weiwei Ding,Jianmin Cao,Jin-Lin Han,Jieshou Li

DOI: https://doi.org/10.1111/j.1742-1241.2008.01765.x

IF: 2.6

2010-01-01

International Journal of Clinical Practice

Abstract:Summary Aims: The aim of this study was to determine the outcome of a modified transjugular intrahepatic portosystemic shunt (MTIPS) in the treatment of the Budd-Chiari syndrome (BCS, occlusion of the hepatic veins). Methods: Eleven patients with severe BCS were selected for MTIPS treatment. Three patients had an acute history (< 2 months) and eight had a subacute or a chronic course of the disease. All patients were associated with variceal bleeding and massive ascites. The diagnosis of BCS was established by duplex sonography, computed tomography scan, magnetic resonance imaging, angiography of hepatic veins and inferior vena cava, and liver biopsy. The shunt was established using conventional self-expandable stents with diameter of 10 cm in all patients. The mean follow-up was 60.55 ± 42.76 months. Results: The shunt reduced the portosystemic pressure gradient from 30.32 ± 7.69 to 9.08 ± 3.43 mmHg and improved the portal flow velocity from 11.24 ± 2.75 to 52.16 ± 13.68 cm/s. Clinical symptoms as well as the biochemical test results improved significantly during 3 weeks after shunt treatment except for one death caused by hepatic failure. Ten patients are alive without clinical symptoms. Three revisions in two patients were needed during the follow-up. The inflation of stenosised shunt was performed in one patient, and the inflation of stenosised shunt and the reimplantation of stent in another patient. The other eight patients had no revisions. Conclusions: Modified transjugular intrahepatic portosystemic shunt provides an excellent outcome in patients with BCS (occlusion of the hepatic veins). It may be regarded as an option for the acute and long-term managements of these patients.
Significance of accessory hepatic vein pressure reduction in treatment of Budd-Chiari syndrome

Jingjun JIANG,Xiaoming ZHANG,Wei LI,Guoyan ZHANG,Xuemin ZHANG,Qingle LI,Yang JIAO,Zhibin HE,Changshun HE,Tao ZHANG

DOI: https://doi.org/10.3978/j.issn.1005-6947.2016.12.013

2016-01-01

Abstract:Objective:To investigate the clinical significance of accessory hepatic vein (AHV) pressure reduction in treatment of Budd-Chiari syndrome (BCS). <br> Methods:The clinical data of 27 BCS patients treated during March 2007 to July 2015 were retrospectively analyzed. Of the patients, 11 cases were male and 16 cases were female, with an average of (46±8) years old;9 cases had lesions in the opening of AHV, 12 cases had occlusion in the inferior vena cava (IVC) and 6 cases had mixed lesions of AHV and IVC. <br> Results:All patients underwent venography and manometry of the AHV and endovascular treatment. Ninepatients with AHV disease underwent balloon dilatation angioplasty of the AHV, and their preoperative AHV pressure dropped from (25±4) cmH2O to (17±3) cmH2O;in the 12 patients with IVC disease, 10 cases underwent balloon dilatation angioplasty of the IVC and 2 cases underwent open surgery, and the preoperative AHV and intrahepatic IVC pressure decreased from (27±6) cmH2O to (15±4) cmH2O and from (27±5) cmH2O to (14±3) cmH2O, respectively;in the 6 cases with both AHV and IVC involvements, the preoperative pressure of AHV and IVC declined from (28±6) cmH2O to (14±4) cmH2O and from (26±5) cmH2O to (13±4) cmH2O, respectively. The abdominal symptoms were significantly relieved 3 days after operation in all patients and the edema in lower limbs was remarkably alleviated in those with IVC lesion, with treatment effective rate of 100%. No complications such as bleeding and pulmonary embolism occurred. Twenty-three patients were followed up for 4 to54 months, doppler ultrasound at 6 months atfer operation showed that the patency rate of original lesion was 100%and, at a later time, IVC re-occlusion occurred in 2 cases which were resolved by second balloon dilatation. <br> Conclusion:AHV pressure reduction can help to alleviate the symptoms of BCS patients, and attention should be paid to the existence of the AHV and the treatment of its problems.
Recent outcomes of liver transplantation for Budd Chiari Syndrome – a study of the European Liver Transplant Registry (ELTR) and affiliated centers

Edo Dongelmans,Nicole Erler,Rene Adam,Silvio Nadalin,Vincent Karam,Sezai Yilmaz,Claire Kelly,Jacques Pirenne,Koray Acarli,Michael Allison,Abdul Hakeem,Dhakshinamoorthy Vijayanand,Dzmitry Fedaruk,Oleg Rummo,Murat Kilic,Arno Nordin,Lutz Fischer,Alessandro Parente,Darius Mirza,William Bennet,Yaman Tokat,Francois Faitot,Barbara B. Antonelli,Gabriela Berlakovich,David Patch,Frederik Berrevoet,Marija Ribnikar,Theophile Gerster,Eric Savier,Salvatore Gruttadauria,Bo-Göran Ericzon,Andrés Valdivieso,Valentin Cuervas-Mons,Baltasar Perez Saborido,Roland S. Croner,Luciano De Carlis,Giulia Magini,Roberta Rossi,Irinel Popescu,Laze Razvan,Stefan Schneeberger,Hans Blokzijl,Laura Llado,Miguel Angel Gomez Bravo,Christophe Duvoux,Vladimír Mezjlík,Gabriel C. Oniscu,Kelsey Pearson,Murat Dayangac,Valerio Lucidi,Olivier Detry,Fernando Rotellar,Caroline den Hoed,Wojciech G. Polak,Sarwa Darwish Murad,

DOI: https://doi.org/10.1097/hep.0000000000000778

IF: 17.298

2024-02-15

Hepatology

Abstract:Background and aims: Management of Budd-Chiari Syndrome (BCS) has improved over the last decades. The main aim was to evaluate the contemporary post-liver transplant (LT) outcomes in Europe. Approach and results: Data from all transplanted patients from 1976-2020 was obtained from the European Liver Transplantation Registry (ELTR). Patients<16yrs, with secondary BCS or hepatocellular carcinoma were excluded. Patient- (PS) and graft survival (GS) before and after 2000 were compared. Multivariate Cox regression-analysis identified predictors of PS and GS after 2000. Supplementary data was requested from all ELTR-affiliated centers and received from 44. 808 patients were transplanted between 2000-2020. One-, five- and ten-year PS was 84%, 77% and 68% and GS was 79%, 70% and 62%, respectively. Both significantly improved, compared to outcomes before 2000 ( p <0.001). Median follow up was 50 months and re-transplantation rate was 12%. Recipient age (aHR:1.04,95%CI:1.02-1.06) and MELD-score (aHR:1.04,95%CI:1.01-1.06), especially above 30, were associated with worse PS, while male sex had better outcomes (aHR:0.63,95%CI:0.41-0.96). Donor age was associated with worse PS (aHR:1.01,95%CI:1.00-1.03) and GS (aHR:1.02,95%CI:1.01-1.03). In 353 patients (44%) with supplementary data, 33% had myeloproliferative neoplasm, 20% underwent TIPS pre-LT and 85% used anticoagulation post-LT. Post-LT anticoagulation was associated with improved PS (aHR:0.29,95%CI:0.16-0.54) and GS (aHR:0.48,95%CI:0.29-0.81). Hepatic artery thrombosis and portal vein thrombosis occurred in 9% and 7%, while recurrent BCS was rare (3%). Conclusion: LT for BCS results in excellent patient- and graft survival. Older recipient or donor age, and higher MELD are associated with poorer outcomes, while long-term anticoagulation improves both patient and graft outcomes.

gastroenterology & hepatology
Point-of-care ultrasound in the diagnosis and treatment of Budd-Chiari syndrome: A rare case report and literature review

Lingzhi Jiang,Ligang Wang,Mingshan Wang,Yuyun Xu,Ye Shen,Xiangming Ye

DOI: https://doi.org/10.1016/j.heliyon.2024.e36192

IF: 3.776

2024-08-17

Heliyon

Abstract:Budd-Chiari syndrome (BCS) is a life-threatening disease characterized by the partial or complete obstruction of hepatic venous outflow anywhere from the liver to the heart. In China, secondary BCS is rare. We present a case of secondary BCS caused by compression of the suprahepatic inferior vena cava (IVC), mainly due to local bile accumulation in the caudate lobe of the liver. This case highlights the scarcity of secondary BCS worldwide and the importance of point-of-care ultrasound (POCUS) in the diagnosis and treatment, especially in critical and comatose patients. Prompt diagnosis and recanalization with POCUS-guided puncture and drainage help improve patient prognosis.
Endovascular treatment of segmental occlusive Budd-Chiari syndrome

Wei-min ZHOU,Hao-rong WU,Xiao-qiang LI,Feng-en LIU

DOI: https://doi.org/10.3760/cma.j.issn.1007-631X.2009.07.016

2009-01-01

Abstract:Objective To evaluate endovascular treatment of segmental occlusive Budd-Chiari syndrome(BCS). Methods We retrospectively analyzed the clinical data of segmental occlusive BCS of 45 cases. Inferior vena cava (IVC) puncture, percutaneons transluminal angioplasty (PTA) and stent implant were performed, respectively. Three-dimensional digital subtraction angiography (3D-DSA) was used to evaluate the IVC lesion from multi-angles and to identify the best work angle in complex BCS cases during endovascular treatment. Results IVC puncture and dilation was successful in 43 cases. The pressure of IVC decreased from (35. 3 ± 3.9)cm H2O to (9.5 ± 2. 0) cm H2O (t = 43. 68, P < 0. 01). The puncture failed in 2 cases and the patients were converted to veno-atrial graft shunt. Acute pericardial tamponade developed during PTA in one case. Postoperatively 35 cases were followed-up for 3 months to 46 months and the follow-up rate was 77. 8%. IVC stent thrombosis was identified in one case necessitating veno-atrial graft shunt 15 months post-operatively. There were no stent migration and hepatic venous obstruction in the remaining cases. The case of pericardial tamponade was cured and discharged after IVC repair. Symptoms disappeared except for intercostal neuralgia during 6 months follow-up. There were no pulmonary embolism and death. Conclusions Good medium and long term result could be achieved after endovascular treatment of segmental occlusive BCS. 3D-DSA is helpful for endovascular treatment of BCS.
Risk factors for and causes and treatment of recurrence of inferior vena cava type of Budd-Chiari syndrome after stenting in China: A retrospective analysis of a large cohort

Wen-Dong Li,Hui-Ying Yu,Ai-Min Qian,Jian-Jie Rong,Ye-Qing Zhang,Xiao-Qiang Li

DOI: https://doi.org/10.1007/s00330-016-4482-4

IF: 7.034

2016-01-01

European Radiology

Abstract:Objectives To explore the risk factors for recurrence of inferior vena cava (IVC)-type Budd–Chiari syndrome (BCS) after stenting and evaluate the feasibility and primary outcomes of endovascular therapies for recurrent BCS. Methods A retrospective analysis of 219 patients was performed to identify risk factors for recurrence. The images of the recurrent patients during follow-up duration and interventional surgery were also reviewed to find the possible reasons of recurrence. The outcome of endovascular therapies for recurrent BCS was evaluated by Kaplan–Meier analysis. Results Among the 219 patients, 172 patients with primary IVC-type BCS underwent stenting and 28 patients experienced recurrence. Multivariate analysis identified age, Child–Pugh score, MELD and total bilirubin as independent recurrent indicators. Possible causes of recurrence include thrombosis in the stent, re-obstruction in or above the stent, and stent-related hepatic vein obstruction. Twenty-five patients with recurrent BCS underwent endovascular therapies with a few complications and achieved a high level of short- and mid-term patency. Conclusion Age, total bilirubin and severity of liver function are the main risk factors for BCS recurrence. These risks might contribute to thrombosis or subsequent fibrous obstruction. Endovascular therapies are effective and safe management options that yield positive outcomes for recurrent BCS. Key Points • Risk factors for recurrent Budd–Chiari syndrome were identified by multivariate analysis . • Causes of recurrent Budd–Chiari syndrome were investigated by assessing radiological images . • There is a correlation between risk factors and causes of recurrence . • Endovascular therapies for recurrent Budd–Chiari syndrome are effective and safe .
The portal hypertension syndrome: etiology, classification, relevance, and animal models

Jaime Bosch,Yasuko Iwakiri

DOI: https://doi.org/10.1007/s12072-017-9827-9

IF: 9.029

2017-10-24

Hepatology International

Abstract:BackgroundPortal hypertension is a key complication of portal hypertension, which is responsible for the development of varices, ascites, bleeding, and hepatic encephalopathy, which, in turn, cause a high mortality and requirement for liver transplantation.AimThis review deals with the present day state-of-the-art preventative treatments of portal hypertension in cirrhosis according to disease stage. Two main disease stages are considered, compensated and decompensated cirrhosis, the first having good prognosis and being mostly asymptomatic, and the second being heralded by the appearance of bleeding or non-bleeding complications of portal hypertension.ResultsThe aim of treatment in compensated cirrhosis is preventing clinical decompensation, the more frequent event being ascites, followed by variceal bleeding and hepatic encephalopathy. Complications are mainly driven by an increase of hepatic vein pressure gradient (HVPG) to values ≥10 mmHg (defining the presence of Clinically Significant Portal Hypertension, CSPH). Before CSPH, the treatment is limited to etiologic treatment of cirrhosis and healthy life style (abstain from alcohol, avoid/correct obesity…). When CSPH is present, association of a non-selective beta-blocker (NSBB), including carvedilol should be considered. NSBBs are mandatory if moderate/large varices are present. Patients should also enter a screening program for hepatocellular carcinoma. In decompensated patients, the goal is to prevent further bleeding if the only manifestation of decompensation was a bleeding episode, but to prevent liver transplantation and death in the common scenario where patients have manifested first non-bleeding complications. Treatment is based on the same principles (healthy life style..) associated with administration of NSBBs in combination if possible with endoscopic band ligation if there has been variceal bleeding, and complemented with simvastatin administration (20-40 mg per day in Child–Pugh A/B, 10–20 mg in Child C). Recurrence shall be treated with TIPS. TIPS might be indicated earlier in patients with: 1) Difficult/refractory ascites, who are not the best candidates for NSBBs, 2) patients having bleed under NSBBs or showing no HVPG response (decrease in HVPG of at least 20% of baseline or to values equal or below 12 mmHg). Decompensated patients shall all be considered as potential candidates for liver transplantation.ConclusionTreatment of portal hypertension has markedly improved in recent years. The present day therapy is based on accurate risk stratification according to disease stage.

gastroenterology & hepatology
Good Clinical Outcomes in Budd–Chiari Syndrome with Hepatic Vein Occlusion

Xinxin Fan,Kai Liu,Yuan Che,Shikai Wang,Xingjiang Wu,Jianmin Cao,Jieshou Li

DOI: https://doi.org/10.1007/s10620-016-4208-0

2016-01-01

Digestive Diseases and Sciences

Abstract:Budd–Chiari syndrome (BCS) with hepatic vein (HV) occlusion is manifested by severe liver damage in acute cases and esophageal variceal bleeding or refractory ascites in chronic cases, which is difficult to differentiate from cirrhotic portal hypertension.

Early evolution of arterial oxygenation in severe community-acquired pneumonia: a prospective observational study.

Staged Management of Budd-Chiari Syndrome Caused by Co-Obstruction of the Inferior Vena Cava and Main Hepatic Veins.

Interventional and Surgical Treatment of Budd-Chiari Syndrome: A Report of 39 Cases

Analysis of Surgical Treatment Results in 120 Cases of Budd-Chiari Syndrome

Interventional Treatment of Budd-Chiari Syndrome:Report of 312 Cases

Advanced Imaging Techniques Used in Direct Portosystemic Shunt Creation in Budd-Chiari Syndrome with Complex Venous Anatomy

Endovascular treatment of Budd-Chiari syndrome with occlusion of hepatic veins

Modified Transjugular Intrahepatic Portosystemic Shunt In The Treatment Of Budd-Chiari Syndrome

INTERVENTIONAL OR SEMI-INTERVENTIONAL TREATMENT FOR BUDD-CHIARI SYNDROME

Clinical profile and outcomes of hepatocellular carcinoma in primary Budd-Chiari syndrome

TIPS with a Twist - The Real Life Management of a Case of Budd-Chiari-related Acute Liver and Subsequent Multiple Organ Failure

Radical Surgery under Genuine Direct Vision for the Treatment of Budd-Chiari Syndrome.

Modified transjugular intrahepatic portosystemic shunt in the treatment of Budd‐Chiari syndrome

Significance of accessory hepatic vein pressure reduction in treatment of Budd-Chiari syndrome

Recent outcomes of liver transplantation for Budd Chiari Syndrome – a study of the European Liver Transplant Registry (ELTR) and affiliated centers

Point-of-care ultrasound in the diagnosis and treatment of Budd-Chiari syndrome: A rare case report and literature review

Endovascular treatment of segmental occlusive Budd-Chiari syndrome

Risk factors for and causes and treatment of recurrence of inferior vena cava type of Budd-Chiari syndrome after stenting in China: A retrospective analysis of a large cohort

The portal hypertension syndrome: etiology, classification, relevance, and animal models

Good Clinical Outcomes in Budd–Chiari Syndrome with Hepatic Vein Occlusion